Publications by authors named "C G Carvalhaes"
Clinical and mycological outcomes of candidaemia and/or invasive candidiasis by Candida spp. and antifungal susceptibility: pooled analyses of two randomized trials of rezafungin versus caspofungin.
Clin Microbiol Infect
February 2025
Objectives: A post hoc analysis used pooled STRIVE/ReSTORE trial data to determine outcomes with rezafungin versus caspofungin by Candida species and antifungal susceptibility.
Methods: The efficacy and safety of once weekly rezafungin 400/200 mg versus once daily caspofungin 70/50 mg was demonstrated in the randomized, double-blind phase 2 STRIVE (NCT02734862) and phase 3 ReSTORE (NCT03667690) trials involving adults with candidaemia and/or invasive candidiasis. In this analysis, data were pooled for patients with a documented Candida infection within 96 hours of randomization who also received ≥1 dose of study drug.
Article Synopsis
- The study evaluated the effectiveness of isavuconazole and other triazoles against 390 non-AFM isolates causing invasive aspergillosis, collected from 41 hospitals between 2017-2021.
- Isavuconazole demonstrated significant antifungal activity, with minimum inhibitory concentrations (MIC) ranging from ≤0.12 to 2 mg/L across different sections of isolates, while some isolates exhibited elevated MIC values.
- Overall, isavuconazole showed potent in vitro activity against non-AFM fungi, though effectiveness varied among and within cryptic species, similar to other triazoles like voriconazole and posaconazole.
Article Synopsis
- * A significant 82.1% of the isolates showed resistance to fluconazole, while 17.9% were resistant to amphotericin B; however, rezafungin remained effective against 96.2% of the isolates.
- * The majority of isolates belonged to South Asian Clade I, with high fluconazole resistance, alongside notable mutations detected in resistance-related genes, highlighting
The VITEK®2 AES β-lactam phenotypes of 488 Enterobacterales from North and Latin America generated by the VITEK®2 were compared to the resistance genotypes provided by whole genome sequencing (WGS). The AES provided phenotypic reports for 447 (91.6 %) isolates, including isolates harbouring carbapenemases (195; 43.
View Article and Find Full Text PDFArticle Synopsis
- Rezafungin, a long-acting echinocandin, is effective for treating candidemia and invasive candidiasis, showing non-inferiority to caspofungin in a Phase 3 study.
- The study included 93 patients on rezafungin and 94 on caspofungin, with similar baseline species distribution across groups and comparable cure rates and mortality outcomes.
- Efficacy was not affected by minimum inhibitory concentration values, and two patients with non-susceptible isolates had successful outcomes with rezafungin treatment.